The Journal of Medical Microbiology, Vol 37, Issue 2 100-103, Copyright © 1992 by Society for General Microbiology

JOURNAL ARTICLE

Protection conferred on mice by combinations of monoclonal antibodies directed against outer-membrane proteins or smooth lipopolysaccharide of Brucella

I. Jacques, A. Cloeckaert, J. N. Limet and G. Dubray
Institut National de la Recherche Agronomique, Laboratoire de Pathologie Infectieuse et Immunologie, Nouzilly, France.

The effect of monoclonal antibodies (MAbs) injected alone or in combination on brucella splenic infection in CD-1 mice was tested 7 and 21 days after a challenge with virulent Brucella abortus 544. Passive immunisation of mice with anti-25-27-kDa MAb alone, or mixed with protective anti-16.5 and anti-36-38-kDa MAbs, or with MAbs of the same specificity which were previously demonstrated to have no activity on CD-1 mice, produced a significant reduction of spleen counts of B. abortus (p less than 0.01). Other combinations of MAbs did not reduce splenic infection in comparison with the untreated control group. BALB/c mice were used to test the possible interference of the immune response of CD-1 mice against MAbs that were produced in BALB/c mice. No reduction of splenic infection was shown with anti-25-27- or -36-38-kDa MAbs, whereas anti-lipopolysaccharide (LPS) MAb which was produced in CBA mice was effective. Combination of anti-protein MAbs with the anti-LPS MAb produced only the effect of the anti-LPS MAb at 7 and 21 days after challenge.

This article has been cited by other articles:

				J. Cassataro, S. M. Estein, K. A. Pasquevich, C. A. Velikovsky, S. de la Barrera, R. Bowden, C. A. Fossati, and G. H. Giambartolomei Vaccination with the Recombinant Brucella Outer Membrane Protein 31 or a Derived 27-Amino-Acid Synthetic Peptide Elicits a CD4+ T Helper 1 Response That Protects against Brucella melitensis Infection Infect. Immun., December 1, 2005; 73(12): 8079 - 8088. [Abstract] [Full Text] [PDF]

				J. Cassataro, C. A. Velikovsky, S. de la Barrera, S. M. Estein, L. Bruno, R. Bowden, K. A. Pasquevich, C. A. Fossati, and G. H. Giambartolomei A DNA Vaccine Coding for the Brucella Outer Membrane Protein 31 Confers Protection against B. melitensis and B. ovis Infection by Eliciting a Specific Cytotoxic Response Infect. Immun., October 1, 2005; 73(10): 6537 - 6546. [Abstract] [Full Text] [PDF]

				C. A. Velikovsky, F. A. Goldbaum, J. Cassataro, S. Estein, R. A. Bowden, L. Bruno, C. A. Fossati, and G. H. Giambartolomei Brucella Lumazine Synthase Elicits a Mixed Th1-Th2 Immune Response and Reduces Infection in Mice Challenged with Brucella abortus 544 Independently of the Adjuvant Formulation Used Infect. Immun., October 1, 2003; 71(10): 5750 - 5755. [Abstract] [Full Text] [PDF]

				D. Monreal, M. J. Grillo, D. Gonzalez, C. M. Marin, M. J. De Miguel, I. Lopez-Goni, J. M. Blasco, A Cloeckaert, and I. Moriyon Characterization of Brucella abortus O-Polysaccharide and Core Lipopolysaccharide Mutants and Demonstration that a Complete Core Is Required for Rough Vaccines To Be Efficient against Brucella abortus and Brucella ovis in the Mouse Model Infect. Immun., June 1, 2003; 71(6): 3261 - 3271. [Abstract] [Full Text] [PDF]

				C. A. Velikovsky, J. Cassataro, G. H. Giambartolomei, F. A. Goldbaum, S. Estein, R. A. Bowden, L. Bruno, C. A. Fossati, and M. Spitz A DNA Vaccine Encoding Lumazine Synthase from Brucella abortus Induces Protective Immunity in BALB/c Mice Infect. Immun., May 1, 2002; 70(5): 2507 - 2511. [Abstract] [Full Text] [PDF]

				A. Al-Mariri, A. Tibor, P. Mertens, X. De Bolle, P. Michel, J. Godefroid, K. Walravens, and J.-J. Letesson Protection of BALB/c Mice against Brucella abortus 544 Challenge by Vaccination with Bacterioferritin or P39 Recombinant Proteins with CpG Oligodeoxynucleotides as Adjuvant Infect. Immun., August 1, 2001; 69(8): 4816 - 4822. [Abstract] [Full Text] [PDF]